Articles

Poll

Podcasts

Slideshows

Videos

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

The Pharmacological Aspects of Adalimumab Biosimilars

Clinicians advocate for an at-parity approach to biosimilars, in which they, their patients, and the local market would have the freedom to choose the product that best suits their needs.

Increasing Legislative Changes May Mark Turning Point in US Biosimilar Adoption

In March, FDA approved biosimilar versions of established biologic drugs for autoimmune diseases and skeletal-related events, adalimumab biosimilars demonstrated sustained efficacy and acceptance among patients, and affirmed CT-P41’s potential as an alternative treatment options in clinical practice.

Biosimilars Month in Review: March 2024

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

An Overview of Adalimumab Biosimilars

Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval. 

The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

The biosimilar recombinant human growth hormone, somatropin, was found to be well-tolerated; only 1.6% of pediatric patients had adverse events suspected to be caused by the injection.

Growth Hormone Somatropin is Effective, Does Not Increase Cancer or Diabetes Risk

Jon Martin, US Commercial Lead of Biosimilars at Organon, discusses the decision to select biosimilar adalimumab-bwwd and its potential implications on the pharmaceutical market.

The US Department of Veterans Affairs Announces Adoption of Adalimumab-bwwd, with Jon Martin

The drug is the first tocilizumab biosimilar with an FDA-approved intravenous and subcutaneous formulation. 

FDA Approves Biosimilar Tocilizumab-aazg for the Treatment of Autoimmune Diseases 

Patients who were naïve to adalimumab tended to switch to other targeted therapies, while those who had been previously treated with adalimumab were more likely to switch back to the reference product. 

Approximately Half of Patients Continued Treatment with Adalimumab Biosimilar ABP 501 at 1 Year

The decision was based on clinical studies demonstrating no clinically meaningful differences between the biosimilar and its reference product. 